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MYC rearrangement can be detected in a subgroup of diffuse large B-cell lymphoma characterized by
unfavorable prognosis. In contrast to Burkitt lymphoma, the correlation between MYC rearrangement and MYC
protein expression in diffuse large B-cell lymphoma is less clear, as approximately one-third of rearranged cases
show negative or low expression by immunohistochemistry. To better understand whether specific
characteristics of the MYC rearrangement may influence its protein expression, we investigated 43 de novo
diffuse large B-cell lymphoma positive for 8q24 rearrangement by FISH, using 14 Burkitt lymphoma for
comparison. Different cell populations (clones), breakpoints (classical vs non-classical FISH patterns), partner
genes (IGH vs non-IGH) and immunostaining were detected and analyzed using computerized image systems. In
a subgroup of diffuse large B-cell lymphoma, we observed different clones within the same tumor distinguishing
the founder clone with MYC rearrangement alone from other subclones, carrying MYC rearrangement coupled
with loss/extra copies of derivatives/normal alleles. This picture, which we defined MYC genetic heteroclonality,
was found in 42% of cases and correlated to negative MYC expression (P= 0.026). Non-classical FISH
breakpoints were detected in 16% of diffuse large B-cell lymphoma without affecting expression (P= 0.040). Non-
IGH gene was the preferential partner of rearrangement in those diffuse large B-cell lymphoma showing MYC
heteroclonality (P= 0.016) and/or non-classical FISH breakpoints (P= 0.058). MYC heteroclonality was not
observed in Burkitt lymphoma and all cases had positive MYC expression. Non-classical FISH MYC breakpoint
and non-IGH partner were found in 29 and 20% of Burkitt lymphoma, respectively. In conclusion, MYC genetic
heteroclonality is a frequent event in diffuse large B-cell lymphoma and may have a relevant role in modulating
MYC expression.
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Diffuse large B-cell lymphoma is the most common
mature aggressive B-cell lymphoma. Despite recent
therapeutic achievements, approximately 40% of
diffuse large B-cell lymphoma cannot be cured,
which indicates the need for further studies focusing
on the characterization of the putative genes
involved in diffuse large B-cell lymphoma pathogen-
esis. In this context,MYC has a relevant role, and the
presence of MYC rearrangement, described in
approximately 5 to 15% of diffuse large B-cell
lymphoma cases, correlates with worse prognosis
and poor response to R-CHOP treatment.1–5
A novel commercial monoclonal antibody has
improved the detection of MYC protein expression
by immunohistochemistry in formalin-fixed paraf-
fin-embedded tissues. Using this antibody, Burkitt
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lymphoma with MYC rearrangement were found to
show intense positive staining for MYC protein in
the vast majority of the cells, supporting the
existence of a strong correlation between gene and
protein status.6–7 In contrast, in MYC rearranged
diffuse large B-cell lymphoma, the association
between rearrangement and protein expression is
less clear, as approximately one-third of cases
with this rearrangement show protein staining in
o40% of the tumor cells.5,8–12
Conventional and molecular cytogenetic studies of
diffuse large B-cell lymphoma have described cases
with MYC rearrangement that are characterized by
complex karyotypes, revealing the presence of
different populations of cells with loss/extra copies
of derivatives of theMYC rearrangement and/or extra
copies of chromosome 8.13–18 The occurrence of
these alterations and their contribution to protein
expression remains unknown.
To further complicate this picture, B-cell lympho-
mas with MYC rearrangement show a great varia-
bility in both the location of the breakpoint in the
8q24 region (involving or not the MYC coding
region) and the partner gene implicated in the
translocation. Non-IGH loci have been reported as
the most common partners in diffuse large B-cell
lymphoma.4,16,19 In addition, when non-IG loci are
involved, breakpoints are usually located outside of
the MYC coding region.15,20–25 The effects of the
different MYC breakpoints and/or rearrangement
partners on MYC expression are not well under-
stood, but recent studies revealed that the IG partner
(mainly represented by the IGH gene) is a negative
predictor of survival in diffuse large B-cell
lymphoma.19,26 Finally, concomitant BCL2 and/or
BCL6 rearrangements in so-called double/triple-hit
lymphomas have been reported in the context
of the diffuse large B-cell lymphoma complex
karyotypes.1,4,16
To better understand whether specific character-
istics of MYC genetic alterations may influence its
protein expression, we performed a detailed analysis
of MYC rearrangement using new computerized
imaging systems in a series of de novo diffuse large
B-cell lymphoma. We described and quantified
different populations of cells with MYC rearrange-
ment and loss/extra copies of the derivatives of the
translocation and/or of the normal allele. Different
types of MYC breakpoints and their correlation to
IGH as a translocation partner were also investigated.
MYC protein staining was evaluated and compared
with all findings.
Materials and methods
Case Selection
A total of 43 de novo diffuse large B-cell lymphoma
cases characterized by MYC rearrangement in 8q24
were retrieved from a series of B-cell lymphomas
investigated for diagnostic purposes during the last
15 years at the Institute of Pathology, Locarno
(Switzerland), Laboratories of Pathology from the
Hospital Clínic of Barcelona and the Hospital del
Mar, Barcelona (Spain), and Institute of Pathology at
the University Hospital, Basel (Switzerland). All
tumors were diagnosed according to World Health
Organization (WHO).27 Formalin-fixed paraffin-
embedded tissue was available for all cases. Clinical
information and follow-up data were obtained for 25
diffuse large B-cell lymphoma patients. To compare
our results with another group of mature aggressive
B-cell lymphomas with MYC rearrangement,
14 Burkitt lymphoma cases were included in
this study.
Immunohistochemistry
Immunohistochemical studies were performed with
a panel of monoclonal and polyclonal antibodies
using a peroxidase-labeled detection system,
standard antigen retrieval protocols and an auto-
mated immunostainer (Roche Ventana Medical
Systems, Baar, Switzerland and Dako Autostainer,
Dako, Copenhagen, Denmark). The panel of anti-
bodies used included CD20, CD79a, CD10, BCL6,
MUM1, BCL2 and Ki-67 (Supplementary Table 1).
In situ hybridization was performed to analyze the
presence of Epstein–Barr virus (EBV). For all of these
markers, a cutoff of 25% stained cells was used to
interpret the results as positive, similar to previously
reported studies, with the exception of BCL2, for
which a cutoff of 50% was used.8 Diffuse large B-cell
lymphoma were subclassified into GCB and non-
GCB according to the Hans’ algorithm.28
MYC protein expression was assessed using the
ready-to-use monoclonal antibody (clone Y69) fol-
lowing the manufacturer’s protocol (Roche Ventana
Medical Systems) and evaluated with a computer-
ized system. Digital images were captured and
analyzed with an Aperio Image Scope (Aperio
Technologies, Vista, CA, USA). Areas of artifacts,
necrosis and other poor quality regions were
excluded from analysis. Expression in 440% of
tumor cells was used as a cutoff to classify a case as
MYC positive, as reported in the literature.7–9
Fluorescence In Situ Hybridization
FISHwas performed on 3- to 4- μm-thick formalin-fixed
paraffin-embedded tissues sections following current
recommendations, as previously described.29,30 The
commercially available MYC split signal probe from
Dako was applied to all cases (MYC FISH DNA Probe,
Split Signal, Dako). This probe was designed to
hybridize upstream and downstream of the MYC
breakpoint cluster region with a green probe (that
binds to a 652-kb segment centromeric to the MYC
breakpoint cluster region on chromosome 8q24) and a
red probe (that binds to a 418-kb segment telomeric to
MYC heteroclonality
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the MYC breakpoint cluster region), respectively,
with a gap of approximately 94 kb. Colocalization of
the probes results in a red/green signal (fusion, 1F)
indicating normal MYC allele, thus a normal cell
display a 2 F FISH pattern (Figure 1a). Translocation
events in the MYC breakpoint cluster region will split
one fusion signal in separate green (1G) and red (1R)
signals, thus resulting in a cell with 1G1R1F FISH
pattern (Figure 1b). As a result of this specific probe
design (http://www.dako.com), breaks occurring in the
sequences centromeric or telomeric to the MYC break-
point cluster region result in 1G2F or 1R2F FISH
pattern, respectively (Figure 1c). Cells carrying one of
these different FISH signals patterns were considered
positive for the presence of MYC rearrangement. For
simplification, on the basis of FISH pattern, cells with
1G1R1F signals were classified as carrying a classical
FISH MYC breakpoint, whereas those with 1G2F or
1R2F signals were grouped as having a non-classical
FISH MYC breakpoint.
In selected cases, MYC was also evaluated by
means of another break-apart probe (Vysis MYC
Break Apart FISH Probe Kit, Abbott Molecular, IL,
USA), which was similarly designed with a dual
color strategy, but covering a larger region at 8q24
with a gap of approximately 1.6Mb. To identify the
IGH locus as a potential partner for MYC rearrange-
ment, an IGH/MYC dual fusion probe (Vysis LSI
IGH/MYC, CEP 8, Tri-color Dual Fusion Transloca-
tion Probe, Abbott Molecular) was used in cases with
available material. FISH for BCL2 and BCL6 using
split signals probes were performed for most diffuse
large B-cell lymphoma cases (BCL2 and BCL6 FISH
DNA Probe, Split Signal, Dako).
Only cases with at least 90% hybridization
efficiency were considered. FISH signal patterns
were interpreted following the criteria of Ventura
et al.31 Ten tonsil sections were used as negative
controls. The cutoff used to establish the presence of
rearrangements with the split signal and dual fusion
probes was 5%.29,31
All FISH experiments were evaluated with a
conventional fluorescence microscope by two expert
operators (AV and VM). In addition, all hybridiza-
tions performed with the MYC Dako split signal
probe were analyzed with the Bioview image-based
quantification system (BioviewDuetTM, NesZiona,
Israel). A minimum of 100 cells with clear non-
overlapping nuclei were selected and automatically
scored for each case. Tissue matching was performed
for the H&E, FISH and immunohistochemistry slides
to ensure that the same tumor areas were evaluated.
Statistical Analysis
Categorical data were compared using Fisher’s exact
test with two-sided P-values, and for ordinal data,
nonparametric tests were used. Statistical analysis
was performed using the SPSS software package
version 21.0 (SPSS, Chicago, IL, USA).
Results
Clinical and Pathological Characteristics of Diffuse
Large B-Cell Lymphoma
Forty-three patients, including 31 males and 12
females, with a mean age of 68 years (range of
38–93 years) were examined in this study. One (2%)
patient had HIV infection, 22/43 (51%) had extra-
nodal presentation and 9/25 (36%) cases died of
disease. All cases showed CD20 and/or CD79a
expression. CD10 was positive in 32/42 (76%),
BCL6 in 36/40 (90%) and MUM1 in 12/34 (35%).
BCL2 expression was detected in 34/41 (83%) cases.
Thirty-two of 40 (80%) cases had a GCB immuno-
phenotype. A high proliferation index (Ki-67490%)
Figure 1 Schematic representation of FISH signal patterns usingMYC split signal probe in aMYC normal cell (a), in aMYC rearranged cell
with classical (b) or non-classical FISH MYC breakpoints (c) (probe design and breakpoints definition should be intended using the Dako
Split Signal probe). Complex FISH patterns showing additional MYC alterations (d). Population carrying MYC rearrangement alone
(founder clone, b or c) and derived subclones with MYC complex pattern (d) resulting in MYC genetic heteroclonality (e).
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was observed in 25/41 (61%) cases. EBV infection
was present in 1/24 (4%) case.
Twenty-eight of 42 (67%) cases were classified as
positive for MYC expression, which was observed in
a range of 42–98% tumor cells, with mean and
median values of 77% and 86%, respectively.
Fourteen cases (33%) were classified as negative
for MYC expression, with a range of 3–35% stained
cells and mean and median values of 18% and 17%,
respectively.
Genetic Characteristics of Diffuse Large B-Cell
Lymphoma
According to FISH patterns of MYC translocation,
two subgroups of diffuse large B-cell lymphoma were
identified (all raw data available in Supplementary
Table 2). Twenty-five of 43 (58%) diffuse large B-cell
lymphoma showed a single pattern of rearrangement
characterized by one copy of a normal MYC allele
and two derivatives (Figures 1b and 1c), which was
observed in 40–98% of the tumor cells (mean: 71%
and median: 73%). We termed this population of
cells as 'MYC founder clone' (ie, cells showing MYC
rearrangement as the sole abnormality). In contrast,
18/43 (42%) cases had the MYC founder clone
(5–60% of cells; mean: 22% and median: 20%) in
combination with two or more clones harboring
MYC rearrangement coupled with additional altera-
tions (extra copies of the normal allele, extra copies
of derivatives, extra copies of both, or deletion of
one of the derivatives; Figure 1d). We called this
complex distribution of MYC rearrangement MYC
genetic heteroclonality (MYC HC) (Figure 1e).
Table 1 shows the FISH patterns details of cases
characterized by MYC HC. No clinical or pathologi-
cal differences were observed in the diffuse large
B-cell lymphoma according to these two subgroups
(detailed in Table 2).
BCL2 and BCL6 rearrangements were detected in
19/36 (53%) and in 13/34 (38%) cases, respectively.
Overall, double hit characterized 19/33 (58%) cases
(12 MYC and BCL2; 7 MYC and BCL6) and triple hit
characterized 5/33 (15%) cases. The presence of
Table 1 Detailed FISH patterns using MYC split signal probe and MYC expression in diffuse large B-cell lymphoma with MYC genetic
heteroclonality
Case
MYC rearrangement
MYC rearrangement
+extra normal allele
MYC rearrangement
+extra/loss
derivatives
MYC rearrangement
+extra normal allele
+extra derivatives
No MYC
rearrangement
MYC IHC
% Of cells Pattern % Of cells Pattern % Of cells Pattern % Of cells Pattern % Of cells Pattern % Of cells
1 27% 1G1R1F 36% 1G1R2F — — — — 37% 2F 97%
2 32% 1G1R1F 55% 1G1R2F — — — — 13% 2F NE
3 46% 1G1R1F 45% 1G1R2F — — — — 9% 2F 35%
4 10% 1G1R1F 90% 1G1R3F — — — — — — 26%
5 18% 1G1R1F 10% 1G1R2F 50% 2G2R1F — — 22% 2F 8%
6 30% 1G1R1F 23% 1G1R2F 14% 1G2R1F 16% 1G2R2F 17% 2F 92%
7 22% 1G1R1F 22% 1G1R2F — — 46% 1G2R2F 10% 2F 86%
8 9% 1G1R1F 28% 1G1R2F — — 27% 2G1R2F 36% 2F 35%
9 19% 1G1R1F 22% 1G1R2F — — 53% 2G1R2F 6% 2F 3%
10 7% 1G1R1F 5% 1G1R2-4F — — 57% 1G2-3R2-4F 31% 2F 13%
11 5% 1G1R1F 49% 1G1R3-6F — — 17% 1G2R3-6F 11+18% 2F+3-6F 92%
12 20% 1G1R1F — — 22% 2G1R1F 35% 2G1R2F 23% 2F 8%
13 60% 1G1R1F — — 25% 2G1R1F — — 15% 2F 24%
14 20% 1G1R1F — — 80% 1G2R1F — — 0% 2F 98%
15 9% 1G1R1F — — 61% 1G0R1F — — 30% 2F 20%
Abbreviations: F, fusion signal (normalMYC allele); G, green signal (MYC centromeric derivative); IHC, immunohistochemistry; NE, not evaluable;
R, red signal (MYC telomeric derivative).
Clones dimensions are intended as the percentage of tumor cells carrying the specific pattern or staining, both evaluated by computerized strategy.
For simplification, only cases with classical FISH MYC breakpoint are listed (full raw data available in Supplementary Table 2).
Table 2 Clinical, pathological and genetic features in diffuse large
B-cell lymphoma regarding MYC genetic heteroclonality
MYC genetic (n=43)
Heteroclonality
(n=18)
No heteroclonality
(n=25)
Clinical
4 60 years 15/18 (83%) 15/25 (60%)
Gender (M:F) 14:4 17:8
Dead of disease 4/11 (36%) 5/14 (26%)
Extranodal location 11/18 (61%) 11/25 (44%)
Immunohistochemical
CD10+ 15/18 (83%) 17/24 (71%)
BCL6+ 17/18 (94%) 19/22 (86%)
MUM1+ 3/15 (20%) 9/19 (47%)
GCB phenotype 15/17 (88%) 17/23 (74%)
BCL2+ 16/18 (89%) 18/23 (78%)
MYC+* 8/17 (47%) 20/25 (80%)
Genetics
IGH/MYC+** 6/14 (43%) 18/22 (82%)
Double/triple hit 12/15 (80%) 15/21 (71%)
*P=0.026, **P=0.016.
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double hit or triple hit was associated with a trend
toward a worse prognosis compared with other cases
carrying MYC as a single hit (P=0.055); all patients
who died of disease showed a double/triple hit.
Double hit and triple hit were found in MYC HC
(7/14, 50% and 4/14, 29%, respectively) and also in
cases without MYC HC (12/19, 63% and 1/19, 5%,
respectively).
The classical FISH MYC breakpoint was found in
36/43 (84%) diffuse large B-cell lymphoma, whereas
the non-classical FISH MYC breakpointwas detected
in 7/43 (16%) cases. Four of the seven cases with
non-classical FISH pattern showed a break centro-
meric to the MYC breakpoint cluster region, whereas
the remaining three had a break telomeric to the
MYC breakpoint cluster region. Cases with non-
classical FISH MYC breakpoint were also analyzed
using the Abbott MYC break-apart probe, confirming
the presence of the rearrangement in all cases. No
difference was observed in the mean number ofMYC
rearranged cells between cases with classical and
non-classical FISH pattern (74%, range: 40–100%, in
classical FISH MYC breakpoint, and 81%, range:
46–100%, in non-classical FISH MYC breakpoint
cases). The comparison of the clinical and patholo-
gical characteristics of the diffuse large B-cell
lymphoma with both types of MYC breakpoints is
summarized in Table 3.
In 36 cases, the presence of an IGH/MYC dual
fusion was studied. Twenty-four cases (67%)
presented the specific translocation t(8;14),
whereas 12 cases had non-IGH rearrangements. The
IGH/MYC translocation was observed in the majority
of cases with a classical FISH MYC breakpoint
(22/30, 73%), but only in 2/6 (33%) cases with a
non-classical FISH MYC breakpoint (P=0.058,
Table 3). An IGH/MYC translocation was observed
in 18/22 (82%) cases without MYC HC, but in 6/14
(43%) cases with MYC HC (P=0.016, Table 2).
Sixteen of 22 (73%) cases with IGH/MYC transloca-
tion and 6/8 (75%) cases without an IGH/MYC
showed double/triple hit. The presence of an IGH/
MYC translocation did not significantly correlate
with overall survival or other clinical–pathological
features (Supplementary Table 3).
Correlation Between MYC Expression and MYC
Genetic Status in Diffuse Large B-Cell Lymphoma
Nine of 14 (64%) cases with lower MYC expression
(o40% of stained cells, classified as MYC immuno-
histochemistry negative) had MYC HC (P=0.026)
(Table 1) and the MYC founder clone was in the
range of 7–60% (mean: 22%, median: 18%). Five
cases with low expression and without MYC HC
showed the MYC founder clone in the range of
46–91% (mean: 73% and median: 74%).
In contrast, only 8/28 (29%) cases with positive
MYC expression had MYC HC. In these cases, the
MYC founder clone was in the range of 5–33% of
cells (mean: 21% and median: 23%). The remaining
cases with positive expression but no MYC HC
showed the MYC founder clone in the range of
40–98% of cells (mean and median: 71%). FISH and
immunohistochemistry images of two cases with
MYC HC are shown in Figures 2a–d.
Owing to the high chromosomal complexity
involving MYC in heteroclonal cases, it was
not possible to establish specific correlations
between other single clones or a specific combina-
tion of these clones and MYC protein expression.
Notably, the FISH pattern with loss of red signal
(corresponding to the derivative chromo-
some carrying MYC telomeric portion) characterized
5/14 (36%) cases with lower MYC expression
(P=0.003).
Considering the breakpoint type observed by
FISH, MYC protein staining was positive in all cases
(7/7) with a non-classical FISH MYC breakpoint
(MYC expression in the range of 42–97% tumor
cells; mean: 85%, median: 93%), and in 21/35 (60%)
cases with the classical breakpoint (MYC expression
in the range of 43–98%; mean: 74%, median: 79%).
The 14 cases classified as negative for MYC expres-
sion had all the classical FISH MYC breakpoint
(P=0.040).
No difference was observed in MYC protein
expression according to IGH or non-IGH genes
as the MYC translocation partner. Sixteen of 25
(64%) cases with positive MYC expression and 8/11
(73%) cases with negative expression showed
IGH/MYC translocation. Cases with IGH/MYC
translocation had a similar number of MYC
stained cells (43–97%, mean: 73%, median: 75%)
Table 3 Clinical, pathological and genetic features in diffuse large
B-cell lymphoma regarding the type of FISH MYC breakpoints
MYC breakpoints (n=43)
Classical FISH
pattern (n=36)
Non-classical FISH
pattern (n=7)
Clinical
4 60 years* 23/36 (72%) 7/7 (100%)
Gender (M:F) 25:11 6:1
Dead of disease 7/20 (35%) 2/5 (40%)
Extranodal location 19/36 (53%) 3/7 (43%)
Immunohistochemical
CD10+ 28/36 (78%) 4/6 (67%)
BCL6+ 32/36 (89%) 4/4(100%)
MUM1+ 10/30 (3%) 2/4 (50%)
GCB phenotype 28/35 (80%) 4/5 (80%)
BCL2+ 28/35 (80%) 6/6 (100%)
MYC+** 21/35 (60%) 7/7 (100%)
Genetics
IGH/MYC+*** 22/30 (73%) 2/6 (33%)
Double/triple hit 23/31 (74%) 4/5 (80%)
MYC genetic
heteroclonality
15/36 (42%) 3/7 (43%)
*P=0.057; **P=0.040; ***P=0.058.
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Figure 2 FISH and immunohistochemistry images of two diffuse large B-cell lymphoma captured by digital system (Bioview and Aperio,
respectively); (a, b) case withMYC genetic heteroclonality and positive MYC expression; (c, d) case withMYC genetic heteroclonality and
negative (low) MYC expression; (e) schematic example for tumoral growth and clonal evolution leading to FISH pattern observed in (c)
(case #9 of Table 1).
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than those with non-IG partner (42–98%, mean:
84%, median: 93%).
Clinical, Pathological and Genetic Characteristics of
Burkitt Lymphoma
The control group comprised 14 Burkitt lymphoma
patients, 10 males and 4 females, with a mean age of
41 years (range: 7–83). Extranodal presentation was
observed in 10/13 (77%) patients. All samples were
positive for CD20 and CD10. BCL6 was also positive
in 12/13 (92%) cases and MUM1 expression was
present in 6/11(55%) cases. The proliferation index
(Ki-67) was higher than 90% in 12/13 (92%) cases,
and EBV infection was detected in 3/12 (25%) cases.
MYC expression was evaluable in 11 of 14 cases, and
all cases were positive, showing a range of 57–95%
stained cells (mean: 83%, median: 87%). MYC
rearrangement by FISH analysis was found in a
range of 65–95% tumor cells (mean: of 83%, median:
85%). MYC HC was not observed in any Burkitt
lymphoma case. All Burkitt lymphoma were char-
acterized by a uniform population carrying the MYC
rearrangement without additional alterations (all raw
data available in Supplementary Table 2).
Ten of 14 (71%) Burkitt lymphoma cases showed a
classical FISH MYC breakpoint and 4 of 14 (29%) a
non-classical FISH MYC breakpoint. Among the
latter cases, two showed a break in the region
centromeric to MYC breakpoint cluster region, and
two in the telomeric one (similarly to diffuse large
B-cell lymphoma, these cases were confirmed using
the MYC break-apart probe from Abbott Molecular).
The cases with a classical FISH MYC breakpoint
showed the rearrangement in 65–95% of cells (mean:
87%, median: 91%), and those with a non-classical
FISH MYC breakpoint in 67–79% of the cells (mean
and median: 72%). Cases with the classical FISH
MYC breakpoint had MYC expression in 57–95% of
cells (mean: 87%, median: 92%), and in those with a
non-classical FISH MYC breakpoint, protein expres-
sion was observed in 60–84% of cells (mean: 73%,
median: 75%). An IGH/MYC dual fusion probe was
used in 10 cases, and 8 (80%) demonstrated the
specific translocation t(8;14)(q24;q32). Seven of eight
(88%) cases with IGH/MYC carried the classical
FISH MYC breakpoint. No clinical or pathological
differences according to type ofMYC breakpoint was
observed in Burkitt lymphoma cases.
Discussion
Diffuse large B-cell lymphoma represents an exceed-
ingly heterogeneous disease both at the clinical and
biological levels. Despite the corroborating role of
MYC alterations as a prognostic marker for diffuse
large B-cell lymphoma,1–5 its assessment represents
a major challenge in clinical practice. A novel
commercial monoclonal antibody has improved the
detection of MYC protein expression,6–7 however,
immunohistochemistry assessment and quantifica-
tion still remains difficult because of highly variable
MYC expression.11–12 In this regard, image digital
analysis and computerized assisted interpretation
may prove to be a valid aid. Applying this strategy
(Aperio) to our series of 43 MYC rearranged diffuse
large B-cell lymphoma, we observed high (440%,
immunohistochemistry positive) and low (o40%,
immunohistochemistry negative) MYC protein
expression in 88% and 12% cases, respectively,
confirming previous observations.5,8–10 Interestingly,
even if all of the investigated diffuse large B-cell
lymphoma samples had a MYC translocation, great
differences were observed in terms of the frequency
of MYC expressing cells: in MYC immunohistochem-
istry positive cases, the median number of stained
cells was 86%, whereas it was 17% in MYC
immunohistochemistry negative cases. To better
understand the possible role of the MYC gene in
the variability of MYC protein expression, we
performed a detailed investigation of MYC rearran-
gement in the whole tumoral context, as well as in
single-cell details.
Relative to MYC rearrangement, regardless of the
specific type of FISH pattern, the percentage of
rearranged cells in our diffuse large B-cell lymphoma
cases ranged from 40% to 98%. Using a computer-
ized imaging system (Bioview), we were able to
specifically describe and quantify all the different
populations of cells within the same tumor, distin-
guishing the MYC founder clone (MYC rearrange-
ment alone) from other populations of cells with
MYC complex patterns, showing the MYC transloca-
tion coupled to further alterations involving MYC.
Reproducing the hypothesis of a clonal evolution
model with a founding clone and multiple sub-
clones, as described for other hematologic
malignancies,32,33 we hypothesize that during tumor
growth, the first pathogenetic event (MYC transloca-
tion) is followed by subsequent changes involving
the MYC derivatives or the normal allele (gain/loss
or extra copies, respectively). The expansion of these
descending cells results in new subclones similar to
the progenitor (sharing MYC translocation) but also
different (carrying additional modifications)
(Figure 2e). This picture defines the presence of
MYC genetic heteroclonality/HC, distinguishing this
precise status from the more general concept of
genetic heterogeneity. Results from conventional
cytogenetic studies (http://cgap.nci.nih.gov/Chromo
somes/CytList) reinforce this hypothesis, and our
findings confirm that FISH is a valid approach to
characterize the presence of MYC HC in tissue
samples.
MYC HC was observed in 42% of diffuse large
B-cell lymphoma and correlated with lower MYC
expression. In contrast, the vast majority of cases
with MYC expression (80%) did not show MYC HC.
In cases with MYC HC, the MYC founder clone
represented a minor population, corresponding to a
median of 20% of tumor cells. Interestingly, in the
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heteroclonal cases with lower expression, the
dimensions of the founder clone and of the MYC
stained population nearly overlapped (median 18%
and 20%, respectively) (Figure 3a). Similarly, in
cases without MYC HC and positive for MYC
expression, the dimension of the MYC founder clone
and the number of overexpressing cells were very
similar (71% vs 74%) (Figure 3d). In Burkitt
lymphoma, this phenomenon was even more evi-
dent, that is, all cases lacked heteroclonality, had
positive expression and showed the MYC founder
clone as a major population (85% and 87%,
respectively). In other words, this precise quantifica-
tion and comparison revealed that in about
two-thirds of diffuse large B-cell lymphoma cases
with MYC rearrangement, the relationship between
founder and expressing clones was strong: the
smaller or bigger the first, the smaller or bigger the
second. In contrast, in the subgroup of cases without
MYC HC and lower MYC expression (corresponding
to about 10% of diffuse large B-cell lymphoma), the
dimension of theMYC founder clone was completely
different from the expressing population, with the
former exceeding by six times the latter (median
dimension: 74% vs 12%) (Figure 3b); the opposite
was observed in the subgroup of cases with MYC HC
but positive MYC expression (about 20%) wherein
the number of expressing cells highly outnumbered
that of the founder clone (median 23% vs 92%,
respectively) (Figure 3c). All these data suggest that
MYC protein expression may be affected by the
presence of heteroclonality (see a putative model in
Figure 3).
From a biological point of view, changes in the
synthesis of MYC protein may be related to primary
events affecting the founder clone itself, or to
secondary events occurring in the derived subclones
during tumor growth. In fact, the majority of MYC
HC showed a reduced expression, indicating the
occurrence in subclone of modifications at the
post-transcriptional/translational level or strictly
affecting MYC gene itself. The fact that five cases
with low MYC expression were characterized by loss
of the red derivative (which is the one that contains
the coding portion of MYC juxtaposed to the
promoter of the partner gene) may support this
hypothesis. In contrast, in those HC cases still
expressing MYC protein, the subclones are likely
not influenced by changes and remain capable of
maintaining the expression. Although the mechan-
isms responsible for the loss of MYC expression are
still unclear, the presence of heteroclonality may
explain the low MYC expression in 10–30% of
diffuse large B-cell lymphoma with MYC
rearrangement.5,8–12,26 Further studies using com-
bined method of FISH and immunofluorescence
(such as FICTION technique) may help to character-
ize more precisely the relationship between MYC
gene and protein status in all these different clones.
MYC HC was observed with similar frequencies in
cases showing MYC rearrangement with classical or
non-classical FISH breakpoints (42% and 43% of
cases, respectively), thus indicating that the break-
point does not have a role in clonal evolution.
Interestingly, MYC HC cases were primarily part-
nered with a non-IGH rearrangement, whereas the
most recurrent partner of cases withoutMYC HC was
the IGH gene, similar to Burkitt lymphoma in our
series, suggesting that IGH-MYC fusion represents a
crucial driver that remains stable during tumoral
expansion without evolving in subclones. Overall,
the IGH partner does not seem to influence protein
expression in our series of diffuse large B-cell
lymphoma, but in cases without HC it was associated
with higher MYC expression, corroborating findings
of a recent study.26
Despite the fact that no peculiar clinical–patholo-
gical features have been observed in diffuse large
B-cell lymphoma with MYC HC, all the aforemen-
tioned characteristics may not only reflect the
Figure 3 Putative model to describe the impact of the presence ofMYC genetic heteroclonality on MYC protein expression in diffuse large
B-cell lymphoma based on the percentage of rearranged and stained cells. M, median.
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complex biology of this disease, but also may
provide a useful tool for defining diffuse large B-cell
lymphoma subgroups. In particular, the recognition
of MYC HC may be a diagnostic clue for daily
practice as it is absent in Burkitt lymphoma.
Further to genetic heteroclonality, the FISH
approach we used to investigate the MYC genetic
status at the single-cell level allowed the determina-
tion of the presence of different breakpoints that may
affect MYC rearrangement. In this context, it is
important to underline that FISH is an indirect
method for breakpoint description and is probe
related; therefore, the terms 'classical vs non-
classical FISH MYC breakpoint' that we defined in
this study should be intended only referring to MYC
split signal probe that we used.
In our cohort, we observed that the most common
breakpoints occur in, or close to, theMYC breakpoint
cluster region (classical FISH MYC breakpoint) both
in diffuse large B-cell lymphoma (84%) and in
Burkitt lymphoma (71%), and in these cases the
preferential translocation partner was the IGH gene.
Non-classical disruptions seems to affect a signifi-
cant subgroup of patients (16% of diffuse large B-cell
lymphoma and 29% of Burkitt lymphoma), espe-
cially those diffuse large B-cell lymphoma with MYC
rearrangements involving a non-IGH gene (P=0.058),
confirming literature data.15,24–25,34 Of note, in our
cohort all 14 diffuse large B-cell lymphoma with
non-classical FISH breakpoint had a positive MYC
expression, whereas all 7 cases with low expression
had a classical break (P=0.040), thus indicating that
a non-classical break does not influence protein
expression and again confirming that loss of MYC
expression may be related to more complex post-
transcriptional/translational mechanisms. No corre-
lation was observed between clinical–pathological
characteristics and different types of breakpoints, but
non-classical FISH breakpoints seemed more
frequent in diffuse large B-cell lymphoma patients
older than 60 years; larger studies are needed to
assess the possible biological reasons for this
observation.
Finally, we investigated the potential relationship
between MYC rearrangement and the concomitant
presence of BCL2 and/or BCL6 rearrangements by
virtue of their common negative prognostic value for
diffuse large B-cell lymphoma. In accordance with
the literature, double hit and triple hit were
frequently observed in our cohort (58% and 15%,
respectively) and indicated a poor prognosis,35 but
the presence of double hit or triple hit was neither
correlated with MYC HC nor with the type of FISH
MYC breakpoints or partners, confirming the biolo-
gical complexity of this disease.
In conclusion, MYC status reflects complex geno-
mic alteration mechanisms in diffuse large B-cell
lymphoma that may specifically rebound on MYC
rearrangement itself (such as non-classical break-
points and/or different partners) or globally to its
distribution in tumoral cell populations. Our study
defines, for the first time, the presence of MYC
genetic heteroclonality in a large series of diffuse
large B-cell lymphoma positive for MYC rearrange-
ment. MYC HC is a frequent event in diffuse
large B-cell lymphoma and has a relevant role in
modulating MYC protein expression. Prospective
studies of larger cohorts are needed to corroborate
these findings and to understand their potential
clinical relevance.
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